Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma

Felipe B. Maegawa, MD, MS; Lauren Shehorn, RN, PhD; Hassan Aziz, MD; John Kettelle, MD; Tun Jie, MD, MS; Taylor S. Riall, MD, PhD

Abstract

IMPORTANCE The selection criteria for hepatectomy for hepatocellular carcinoma (HCC) is not well established. The role of noninvasive fibrosis markers in this setting is unknown in the US population.

OBJECTIVE To evaluate whether aspartate aminotransferase–platelet ratio index (APRI) and fibrosis 4 (Fib4) values are associated with perioperative mortality and overall survival after hepatectomy for HCC.

DESIGN, SETTING, AND PARTICIPANTS In a multicenter cohort study, Veterans Administration Corporate Data Warehouse was used to evaluate a retrospective cohort of 475 veterans who underwent hepatectomy for HCC between January 1, 2000, and December 31, 2012, in Veterans Administration hospitals. Data analysis occurred between September 30, 2016, and December 30, 2017. Logistic regression, survival analysis, and change in concordance index analysis were performed to evaluate the association between APRI and Fib4 values and mortality.

EXPOSURES The cohort was stratified based on preoperative APRI and Fib4 values. Analysis was performed accounting for the validated and established predictors of outcome.

MAIN OUTCOMES AND MEASURES Thirty-day mortality, 90-day mortality, and overall survival were the primary outcomes. An APRI value greater than 1.5 was considered high risk (cirrhosis), and an Fib4 value greater than 4.0 was considered high risk (advanced fibrosis). Portal hypertension (diagnosis of ascites or encephalopathy indicates presence of portal hypertension) and Child-Turcotte-Pugh (CTP) class (A indicates preserved liver function; B, mild to moderate liver dysfunction) served as 2 other measures of liver function.

RESULTS A total of 475 patients with HCC underwent hepatectomy. The mean (SD) age was 65.6 (9.4) years; Model for End-Stage Liver Disease score, 8.9 (3.1); and body mass index, 28.1 (4.9) (calculated as weight in kilograms divided by height in meters squared). A total of 361 patients (76.0%) were men, 294 (61.9%) were white; 308 (64.8%) were hepatitis C positive, and 346 (72.8%) were categorized as CTP class A. The most common surgical procedure was partial lobectomy, with 321 (67.6%) procedures. The APRI value greater than 1.5 vs 1.5 or lower was associated with increased 30-day mortality (odds ratio [OR], 6.45; 95% CI, 2.80-14.80) and 90-day mortality (OR, 2.65; 95% CI, 1.35-5.22), as was Fib4 greater than 4.0 vs Fib4 4.0 or lower for 30-day mortality (OR, 5.41; 95% CI, 2.35-12.50) and 90-day mortality (OR, 2.74; 95% CI, 1.41-5.35). Survival analysis showed that overall survival was significantly different for APRI greater than 1.5 vs 1.5 or lower (mean survival time, 3.6 vs 5.4 years; log-rank P < .001) and Fib4 greater than 4.0 vs 4.0 or lower (mean survival time, 4.1 vs 5.3 years; log rank P = .01). Adjusted Cox proportional hazards

Key Points

Question Are the noninvasive fibrosis markers aspartate aminotransferase–platelet ratio index and fibrosis 4 associated with perioperative mortality and overall survival after hepatectomy for hepatocellular carcinoma?

Findings In this cohort study of 475 US veterans, aspartate aminotransferase–platelet ratio index and fibrosis 4 were independently associated with increased 30- and 90-day mortality and worse overall survival. They were shown to improve the estimation of postoperative mortality.

Meaning This study suggests that the incorporation of aspartate aminotransferase–platelet ratio index and fibrosis 4 in the selection criteria of hepatectomy for hepatocellular carcinoma may be warranted.

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

JAMA Network Open. 2019;2(1):e187142. doi:10.1001/jamanetworkopen.2018.7142

January 18, 2019 1/11

Downloaded From: https://jamanetwork.com/ on 04/30/2019
regression analysis revealed that elevated APRI was significantly associated with worse survival (hazard ratio [HR], 1.13; 95% CI, 1.03-1.23) but Fib4 values were not (HR, 1.04; 95% CI, 0.99-1.09). Change in concordance index showed that APRI and Fib4 improved the ability of CTP class and portal hypertension to predict postoperative mortality.

CONCLUSIONS AND RELEVANCE Elevated APRI and Fib4 values, which are noninvasive markers of fibrosis, were associated with higher perioperative mortality. The APRI was also associated with worse overall survival. Use of APRI and Fib4 measures improved the ability of established markers to predict postoperative mortality. These findings suggest incorporating APRI and Fib4 to the selection process for hepatectomy for HCC as predictors associated with mortality may be warranted.

JAMA Network Open. 2019;2(1):e187142. doi:10.1001/jamanetworkopen.2018.7142

Introduction

Hepatectomy and liver transplant are the main curative therapies for hepatocellular carcinoma (HCC).\(^1\) Intention-to-treat studies have demonstrated similar overall survival for these therapies.\(^2,3\) The selection criteria for HCC resection are not well established.\(^4\) The National Comprehensive Cancer Network guidelines for HCC state that patients with preserved liver function, resectable disease, who fit United Network for Organ Sharing criteria, could be considered for resection or transplant, and there remains controversy over which initial strategy is preferable.\(^1\) Hepatocellular carcinoma is currently the fastest rising cause of cancer-related deaths in the United States.\(^5\) Although the incidence of HCC tripled between 1975 and 2005, the 5-year survival rate remains approximately 25%.\(^6\) However, this survival rate could be greater than 70% when curative therapy is applied to early-stage HCC.\(^2,3,7,8\)

Hepatic fibrosis is associated with an increased risk of postoperative liver failure and mortality after resection for HCC.\(^9\) The noninvasive fibrosis markers (NIFMs) aspartate aminotransferase-platelet ratio index (APRI) and fibrosis 4 (Fib4) have been shown to accurately predict the presence of cirrhosis and severe fibrosis when validated with liver biopsy findings.\(^10,11\) Studies conducted in Asian patients with hepatitis B and HCC demonstrated that abnormal levels of NIFMs were associated with worse postoperative outcomes after hepatectomy.\(^12,14\) However, to our knowledge, the role of these markers in the US population has not been studied. The aim of this study was to examine the association of APRI and Fib4 with perioperative mortality and overall survival after HCC resection among US veterans. We hypothesized these NIFMs independently associated with perioperative mortality and overall survival after hepatectomy for HCC.

Methods

Data Source and Study Cohort

The Veterans Administration (VA) Corporate Data Warehouse database was used. The Corporate Data Warehouse is a robust and comprehensive database that abstracts clinical information directly from the computerized patient record system from VA hospitals. Data were accessed, managed, and analyzed within the VA informatics and computing infrastructure. From January 1, 2000, to December 31, 2012, all patients with the diagnosis of HCC were identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 155.0 (liver cell carcinoma) and excluding patients with ICD-9-CM code 155.1 (intrahepatic bile duct carcinoma).\(^15\) We included all patients undergoing hepatectomy using the Current Procedural Terminology codes 47120 (partial lobectomy), 47125 (total left lobectomy), 47130 (total right lobectomy), and 47122 (trisegmentectomy). Data abstraction and management started September 30, 2016, and the analysis was completed on December 30, 2017.
The study protocol was reviewed and approved by the institutional review board of the Southern Arizona VA Health Care System, which also waived informed patient consent because this project was limited to retrospective deidentified data analysis. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.  

### Patient Demographics and Clinical Factors

Demographic, laboratory, and clinical data were ascertained at the time of resection. Race/ethnicity information was defined by the participants and was available on the CDW database. The preoperative laboratory data were obtained from the closest date to surgery. Liver function was determined using Model for End-Stage Liver Disease (MELD) score (score of 6-9 indicates normal liver function; ≥10 indicates liver dysfunction) and Child-Turcotte-Pugh (CTP) class (A indicates preserved liver function; B, mild to moderate liver dysfunction), as previously described.  

The presence of advanced fibrosis and cirrhosis was determined using the NIFMs Fib4 and APRI, respectively. Based on the studies that validated these NIFMs with liver biopsy and meta-analysis, the cutoff value for Fib4 was 4.0 (>4.0 indicates advanced fibrosis) and for APRI, 1.5 (>1.5 indicates cirrhosis).  

\[
\text{Fib4} = \frac{[\text{age (years)} \times \text{AST level (U/L)}]}{[\text{platelet count (10}^9\text{)} \times \sqrt{\text{ALT level (U/L)}}]},
\]

\[
\text{APRI} = \frac{[\text{AST level (U/L)} / \text{AST (upper limit of normal)}]}{\text{platelet count (10}^9\text{)} \times 100},
\]

where ALT indicates alanine aminotransferase and AST indicates aspartate aminotransferase.  

The main outcomes were defined as perioperative mortality and long-term survival; 30- and 90-day mortality were examined. Long-term survival was evaluated with overall survival comparison for patients with at least 1-month follow-up.  

### Statistical Analysis

A 2-tailed, unpaired t test or Mann-Whitney test was used for univariate comparisons of continuous variables, and Pearson χ² or Fisher exact test was used for comparison of categorical variables. A logistic regression model was used to evaluate the association between APRI and Fib4 and perioperative mortality. Overall survival was calculated from the date of surgery to date of death or last follow-up. The Kaplan-Meier method was used to plot the survival curves, and comparisons were performed with the log-rank test. Cox proportional hazards regression analysis was performed to evaluate the association between APRI and Fib4 levels with long-term survival. Previously established predictors of perioperative mortality were included in the multivariate models. To evaluate the predictive contribution of APRI and Fib4, their association with the concordance index of the predictive model composed of the established predictors of outcome (CTP and portal hypertension) were examined as previously described.  

Complete case analysis was used for missing data. Statistical comparisons were 2-sided, and P values <.05 were considered significant. The statistical analysis was conducted using the SAS Enterprise Guide, version 7.1 (SAS Institute Inc).

### Results

### Patient and Operative Characteristics of the Whole Cohort

A total of 11,497 veterans were diagnosed with HCC between January 1, 2000, and December 31, 2012. Of those, 475 patients (4.1%) underwent liver resection. The clinical characteristics of the whole cohort are outlined in Table 1. The mean (SD) age was 65.6 (9.4) years, 361 (76.0%) were men, and 294 (61.9%) were white. Hepatitis C, present in 308 patients (64.8%), was the most common cause of liver disease. Partial lobectomy was performed in 321 patients (67.6%), whereas major hepatectomy was performed in 154 patients (32.4%). As expected for surgical patients, most had neither ascites (349 [73.5%]) nor encephalopathy (420 [88.4%]), and CTP class A was the most
common level (346 [72.8%]). The mean (SD) values were 8.9 (3.1) for MELD, 1.1 (1.3) for APRI, and 3.4 (2.7) for Fib4. The mean follow-up period was 4.7 (3.8) years. The 30- and 90-day mortality rates were 5.9% and 10.1%, respectively. The median overall survival was 3.9 (95% CI, 3.3-4.5) years.

**APRI and Fib4 Association With Perioperative Mortality and Survival**

Logistic regression was performed to examine the association between APRI and Fib4 and the 30- and 90-day mortality. Compared with patients with APRI values 1.5 or lower, multivariable analysis revealed that APRI greater than 1.5 was associated with worse 30-day (OR, 6.45; 95% CI, 2.80-14.80; \( P < .001 \)) and 90-day (OR, 2.65; 95% CI, 1.35-5.22; \( P = .005 \)) mortality. Likewise, multivariable analysis showed that, compared with Fib4 levels of 4.0 or lower, Fib4 levels greater than 4.0 were associated with worse 30-day (OR, 2.10; 95% CI, 1.12-3.97; \( P = .022 \)) and 90-day (OR, 1.55; 95% CI, 0.87-2.77; \( P = .158 \)) mortality.

**Table 1. Baseline Clinical Characteristics of 475 Patients Who Underwent Liver Resection for Hepatocellular Carcinoma**

| Variable                          | Patients (N = 475) |
|-----------------------------------|--------------------|
| Age, mean (SD), y                 | 65.6 (9.4)         |
| Sex, No. (%)                      |                    |
| Women                             | 8 (1.7)            |
| Men                               | 361 (76.0)         |
| Missing                           | 106 (22.3)         |
| Race, No. (%)                     |                    |
| White                             | 294 (61.9)         |
| Other                             | 143 (30.1)         |
| Missing                           | 38 (8.0)           |
| BMI, mean (SD)                    | 28.1 (4.9)         |
| Cirrhosis cause, No. (%)          |                    |
| Non-HCV                           | 167 (35.2)         |
| HCV                               | 308 (64.8)         |
| Hepatectomy type, No. (%)         |                    |
| Major lobectomy (right, left, trisegmentectomy) | 154 (32.4)         |
| Partial lobectomy                 | 321 (67.6)         |
| Bilirubin, mean (SD), mg/dL       | 1.13 (0.4)         |
| Albumin, mean (SD), g/dL          | 3.97 (3.2)         |
| Missing, No. (%)                  | 22 (4.6)           |
| Creatinine, mean (SD), mg/dL      | 1.17 (0.46)        |
| INR, mean (SD)                    | 1.11 (0.1)         |
| Ascites, No. (%)                  |                    |
| No                                | 349 (73.5)         |
| Yes                               | 126 (26.5)         |
| Encephalopathy, No. (%)           |                    |
| No                                | 420 (88.4)         |
| Yes                               | 55 (11.6)          |
| CTP class, mean (SD), points*     | 5.9 (1.1)          |
| A                                 | 346 (72.8)         |
| B                                 | 129 (27.2)         |
| MELD score, mean (SD)*            | 8.9 (3.1)          |
| APRI, mean (SD)*                  | 1.1 (1.3)          |
| Fib4, mean (SD)*                  | 3.4 (2.7)          |
| Follow-up, mean (SD), y           | 4.7 (3.8)          |
| Mortality, No. (%)                |                    |
| 30-Day                            | 28 (5.9)           |
| 90-Day                            | 48 (10.1)          |
| Overall survival, y               |                    |
| Mean (SE)                         | 5.1 (0.2)          |
| Median (95% CI)                   | 3.9 (3.3-4.5)      |

Abbreviations: APRI, aspartate aminotransferase-platelet ratio index; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CTP, Child-Turcotte-Pugh; Fib4, fibrosis 4; HCV, hepatitis C virus; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease.

SI conversion units: To convert albumin to grams per liter, multiply by 10; bilirubin to micromoles per liter, multiply by 17.104; creatinine to micromoles per liter, multiply by 88.4.

* CTP A indicates preserved liver function; B, mild to moderate liver dysfunction.

\* MELD score of 6 to 9 indicates normal liver function; 10 or higher indicates liver dysfunction.

\* An APRI value greater than 1.5 was considered high risk (cirrhosis).

\* An Fib4 value greater than 4.0 was considered high risk (advanced fibrosis).
associated with worse 30-day (OR, 5.41; 95% CI, 2.35-12.50; \( P < .001 \)) and 90-day (OR, 2.74; 95% CI, 1.41-5.35; \( P = .003 \)) mortality (Table 2).

Kaplan-Meier survival analysis showed that patients with APRI levels greater than 1.5 had worse overall survival than patients with APRI levels of 1.5 or lower (mean survival time, 3.6 vs 5.4 years; log-rank test \( P < .001 \)) (Figure 1A). The median survival for patients with APRI greater than 1.5 and APRI 1.5 or less were 2.2 and 4.3 years, respectively. When patients were stratified by Fib4 index, the overall survival between patients with Fib4 greater than 4.0 was significantly worse than patients with Fib4 of 4.0 or lower (mean survival, 4.1 vs 5.3 years; log-rank test \( P = .01 \)) (Figure 1B). The median survival for patients with Fib4 greater than 4.0 and 4.0 or lower were 2.7 and 4.3 years.

### Table 2. Multivariable Logistic Regression Analysis of APRI and Fib4 for 30- and 90-Day Mortality After Hepatectomy for Hepatocellular Carcinoma

| Variable Category | 30-d Mortality OR (95% CI) | \( P \) Value | 90-d Mortality OR (95% CI) | \( P \) Value |
|-------------------|---------------------------|--------------|---------------------------|--------------|
| APRI† >1.5        | 6.45 (2.80-14.8)          | <.001        | 2.65 (1.35-5.22)          | .005         |
| CTP classb B      | 3.56 (1.37-9.30)          | .009         | 3.51 (1.64-7.51)          | <.001        |
| Portal hypertension Present | 7.27 (2.20-24.1) | .001         | 2.74 (1.20-6.28)          | .01          |
| Fib4c >4.0        | 5.41 (2.35-12.5)          | <.001        | 2.74 (1.41-5.35)          | .003         |
| CTP classb B      | 3.53 (1.35-9.17)          | .009         | 3.41 (1.58-7.34)          | .002         |
| Portal hypertension Present | 7.18 (2.17-23.7) | .001         | 2.82 (1.22-6.51)          | .01          |

Abbreviations: APRI, aspartate aminotransferase-platelet ratio index; CTP, Child-Turcotte-Pugh; Fib4, fibrosis 4; OR, odds ratio.
† An APRI value greater than 1.5 was considered high risk (cirrhosis).
‡ CTP class B was considered high risk (liver dysfunction).
§ An Fib4 value greater than 4.0 was considered high risk (advanced fibrosis).
respectively. Multivariate Cox proportional hazards regression model analysis was conducted. After adjusting for CTP and the presence of portal hypertension, APRI was associated with worse overall survival after hepatectomy for HCC (hazard ratio [HR], 1.13; 95% CI, 1.03-1.23; \( P = .007 \)). However, Fib4 was not significantly associated with worse overall survival (HR, 1.04; 95% CI, 0.99-1.09; \( P = .06 \)).

**Change in the Concordance Index and APRI and Fib4**

Concordance index is similar to the area under the receiver operating characteristic (ROC) curve and measures the probability that, given 2 random patients, the one with the worse outcome is predicted to have a worse outcome.\(^2^2\) To evaluate whether APRI and Fib4 could more accurately predict the postoperative mortality and overall survival after hepatectomy for HCC, these NIFMS were added to the model containing the established predictors: CTP class and portal hypertension. Table 3 reports 3 regression models for the prediction of 30- and 90-day mortality and overall survival. Each of the 3 models lacks 1 variable, and they are compared with the full model containing all variables (reference model). The predictive accuracy of 30-day mortality was improved by 0.12 (\( P = .009 \)) when APRI was incorporated into the established model (CTP and portal hypertension). Likewise, the ability to predict 90-day mortality was improved by adding APRI to the established model by 0.05 (\( P = .01 \)).

In addition, APRI improved the overall survival prediction by 0.18 (\( P < .001 \)). Table 3 also demonstrates the association between Fib4 and the prediction accuracy of perioperative mortality and overall survival. The improvement of the predictive accuracy of 30- and 90-day mortality by adding Fib4 to the model was 0.13 (\( P = .004 \)) and 0.07 (\( P = .01 \)), respectively. The long-term survival prediction was improved by 0.17 (\( P = .003 \)). Figure 2 illustrates the ROC curves and their respective areas under the curve, demonstrating the association between APRI and Fib4 with the predictive accuracy of 30- and 90-day mortality in patients after hepatectomy for HCC.

**Discussion**

To our knowledge, this is the largest Western series to examine the role of NIFMs in patients undergoing hepatectomy for HCC. This study demonstrates the association of APRI and Fib4 with the perioperative mortality and overall survival after hepatectomy for HCC. Using cutoff values described and validated by previous studies, both APRI and Fib4 were independently associated with increased 30- and 90-day mortality.\(^1^0,1^1,2^0,2^3\) In addition, APRI was associated with worse overall survival, after adjusting for CTP class and portal hypertension. Child-Turcotte-Pugh classification and portal hypertension are the most validated and established predictors of outcome after liver resection, and are broadly used for selection of patients for liver resection for HCC.\(^2^4\) The perioperative mortality

| Concordance Index Model | 30-d Mortality Concordance Index | 90-d Mortality Concordance Index | Long-term Survival Concordance Index |
|-------------------------|---------------------------------|---------------------------------|-------------------------------------|
|                         | Decrease (95% CI)                | Decrease (95% CI)                | Decrease (95% CI)                   |
|                         | \( P \) Value                    | \( P \) Value                    | \( P \) Value                       |
| APRI\(^a\)              |                                 |                                 |                                     |
| CTP, portal hypertension, APRI | Full model [reference]         | NA                              | Full model [reference]              |
|                         | 0.06 (−0.01 to 0.15)            | .13                             | 0.008 (−0.02 to 0.04)               |
|                         | \( P = .13 \)                    | .67                             | \( P = .008 \)                      |
| APRI                   | Full model [reference]          | NA                              | Full model [reference]              |
|                         | 0.04 (−0.03 to 0.06)            | .59                             | 0.04 (−0.03 to 0.12)                |
|                         | \( P = .04 \)                    | .26                             | \( P = .006 \)                      |
| APRI                   | Full model [reference]          | NA                              | Full model [reference]              |
|                         | 0.12 (0.03 to 0.22)             | .009                            | 0.05 (0.01 to 0.10)                 |
|                         | \( P = .01 \)                    | .01                             | \( P = .08 \)                      |
| FIB4                   |                                 |                                 |                                     |
| CTP, portal hypertension, Fib4 | Full model [reference]         | NA                              | Full model [reference]              |
|                         | 0.03 (−0.03 to 0.10)            | .35                             | 0.006 (−0.03 to 0.04)               |
|                         | \( P = .03 \)                    | .74                             | \( P = .10 \)                      |
| CTP                    |                                 |                                 |                                     |
|                         | 0.001 (−0.01 to 0.01)           | .89                             | 0.03 (−0.02 to 0.09)                |
|                         | \( P = .10 \)                    | .20                             | \( P = .07 \)                      |
| CTP                    |                                 |                                 |                                     |
|                         | 0.13 (0.04 to 0.22)             | .004                            | 0.07 (0.01 to 0.14)                 |
|                         | \( P = .06 \)                    | .01                             | \( P = .06 \)                      |

Abbreviations: APRI, aspartate aminotransferase-platelet ratio index; CTP, Child-Turcotte-Pugh; Fib4, fibrosis 4; NA, not applicable.

\(^a\) An APRI value greater than 1.5 was considered high risk (cirrhosis).  
\(^b\) CTP class B was considered high risk (liver dysfunction).  
\(^c\) An Fib4 value greater than 4.0 was considered high risk (advanced fibrosis).
rate within 90 days from surgery for the 475 patients was found to be 10.1%, highlighting the need for better predictors of postoperative outcomes.

The present study is unique for being what we believe to be the first to demonstrate how APRI and Fib4 contribute to the ability to predict the perioperative mortality and overall survival beyond what is achieved by the established predictors. This improvement indicated by APRI and Fib4 was demonstrated using the concordance index change method. The decrease in the concordance index associated with the addition of APRI or Fib4 to the regression models was statistically significant for the prediction of 30- and 90-day mortality and overall survival. These findings suggest that both APRI and Fib4 contribute to the prediction of short- and long-term survival outcomes after resection of HCC, beyond what is achieved by CTP and portal hypertension.

This study supports the findings of other authors that APRI is independently associated with poor overall survival after liver resection for HCC.\textsuperscript{12-14} Hung et al.\textsuperscript{12} and Shen et al.\textsuperscript{13} showed that APRI was associated with worse disease-free and overall survival. Hung et al.\textsuperscript{12} evaluated APRI as a

---

**Figure 2. Sensitivity and Specificity of Aspartate Aminotransferase–Platelet Ratio Index (APRI) and Fibrosis 4 (Fib4) as Indicators of Mortality**

Receiver operating characteristic (ROC) curves with associated areas under the curve. A and B, APRI and Fib4 improvement of the predictive ability of the models for 30-day mortality. C and D, APRI and Fib4 improvement of the predictive ability of the models for 90-day mortality. *P* values represent the differences in areas under of the curve between the full model vs the model without APRI or Fib4 (Child-Turcotte-Pugh [CTP], portal hypertension). An APRI value greater than 1.5 was considered high risk (cirrhosis), and an Fib4 value greater than 4.0 was considered high risk (advanced fibrosis).
surrogate marker of hepatic fibrosis in 76 patients with hepatitis B who underwent hepatectomy for solitary and small HCC and reported that APRI was a reliable marker for assessing fibrosis and predicting survival. More recently, Shen et al, examining a cohort of 332 patients, reported that APRI was associated with worse disease-free and overall survival. The populations of these studies were predominantly patients with hepatitis B. A study from Japan, examining a large cohort of patients with hepatitis C, evaluated the association between APRI and postoperative liver failure. The investigators demonstrated that APRI was independently associated with an increased risk of postoperative liver failure. 16

To our knowledge, the present study is the first to report the association between APRI and worse 30- and 90-day postoperative mortality. Furthermore, this appears to be the first report of the association of Fib4 with 30- and 90-day mortality after hepatectomy for HCC. Dong et al 23 examined the association of Fib4 with postoperative complications and intraoperative blood loss in a large cohort of patients with hepatitis B (n = 350). They demonstrated that Fib4 was independently associated with adverse postoperative outcomes. Toyoda et al 25 evaluated the association of Fib4 and long-term outcome after resection for HCC in a large series of 431 patients. They found that Fib4 was associated with worse disease-free and overall survival. These findings corroborate the results of our analysis. However, the present analysis differs from these previous studies because it was based on a large cohort of US veterans. The main cause of liver disease in these patients was hepatitis C. Moreover, this study appears to be the first to evaluate the predictive ability of APRI and Fib4 and their contribution to the established predictors of liver resection outcomes in an organized and methodologic manner.

For patients with CTP A without portal hypertension with resectable HCC, there is still controversy on which is the preferable initial strategy: liver resection or transplantation. The optimal selection criteria for these therapies have yet to be established. 1 In this analysis, 4.1% of the patients with HCC underwent liver resection, which is consistent with previous studies on HCC treatment. Davila et al 26 also using the VA Hepatitis C Clinical Case Registry, reported that 4.4% of veterans with HCC underwent liver resection. Forner et al 24 reported that only of 5% to 10% of patients are candidates for hepatectomy, because most centers restrict surgery to patients with good performance status, a single tumor, preserved liver function, and the absence of portal hypertension and vascular invasion. Child-Turcotte-Pugh class and portal hypertension are integral parts of the Barcelona Clinic Liver Cancer Staging System, which is the standard of care for HCC management in Western countries. 24 Therefore, CTP class and portal hypertension were used in our analysis. The outcomes after hepatectomy for HCC have improved over the past decades, given better surgical techniques and perioperative care. 27,28 Patient selection has played a significant role in reducing perioperative morbidity and mortality. Therefore, the Barcelona Clinic Liver Cancer Staging System could be further refined. 24

Noninvasive fibrosis markers, such as APRI and Fib4, are attractive markers because they are easily accessible and determined with routine preoperative laboratory tests. Another unique characteristic of APRI and Fib4 is that they include the platelet count, which is useful because a low platelet count has been shown to be associated with increased perioperative morbidity and mortality. 29,30 In addition, APRI and Fib4 are NIFMs that were validated prospectively with liver biopsy. 10,11 Wai et al 11 demonstrated that APRI can predict cirrhosis with an area under the ROC curve of 0.94. Sterling et al 10 evaluated the discriminative ability of Fib4 in predicting liver fibrosis, reporting an area under the ROC curve of 0.756 for severe fibrosis. Therefore, APRI and Fib4 are good predictors of cirrhosis and fibrosis, respectively. Liver fibrosis and cirrhosis have been described as markers of impaired hepatic regeneration and increased risk of postoperative liver failure after hepatectomy. 6,31 These findings, associated with the results of the present study, indicate that APRI and Fib4 are potential predictors of postoperative mortality after hepatectomy for HCC.
Limitations
This study has several limitations, which are inherent to its observational retrospective design. Some unmeasured patient characteristics could have changed the results, in particular, the lack of information on preoperative comorbidities. However, the large number of patients of this cohort and the analysis accounting for the validated predictors of surgical outcomes helped to minimize possible selection bias. The VA CDW database constitutes predominately white, male patients. Therefore, the results of this study may not be generalizable to the overall population. Information on HCC recurrence and specific cause of death were not available. In addition, information on postoperative complications was not ascertained. Therefore, it is unknown whether perioperative mortality was related to liver failure or other causes.

Conclusions
This study suggests that APRI greater than 1.5 and Fib4 greater than 4.0 were independently associated with increased 30- and 90-day mortality after hepatectomy for HCC. In addition, APRI was independently associated with worse overall survival. The contribution of APRI and Fib4 to improve the ability of established markers in predicting perioperative mortality and overall survival was supported by valid methods. These findings suggest that incorporating APRI and Fib4 in the selection process for hepatectomy for HCC as new predictors of mortality may be warranted.

ARTICLE INFORMATION
Accepted for Publication: November 27, 2018.
Published: January 18, 2019. doi: 10.1001/jamanetworkopen.2018.7142
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Maegawa FB et al. JAMA Network Open.
Corresponding Author: Felipe B. Maegawa, MD, MS, Southern Arizona Veterans Affairs Health Care System, 3601 S Sixth Ave, Surgical Care Line-2-112, Tucson, AZ 85723 (fmaegawa@umich.edu).
Author Affiliations: Surgical Care Line, Southern Arizona Veterans Affairs Health Care System, Tucson (Maegawa, Kettelle); Department of Surgery, University of Arizona, Tucson (Maegawa, Kettelle, Jie, Riall); Quality Management, Robley Rex Veterans Affairs Medical Center, Louisville, Kentucky (Shehorn); Department of Surgery, University of Southern California, Los Angeles (Aziz).
Author Contributions: Drs Maegawa and Shehorn had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Maegawa, Kettelle, Jie, Riall.
Acquisition, analysis, or interpretation of data: Maegawa, Shehorn, Aziz.
Drafting of the manuscript: Maegawa, Shehorn.
Critical revision of the manuscript for important intellectual content: Maegawa, Aziz, Kettelle, Jie, Riall.
Statistical analysis: Maegawa.
Administrative, technical, or material support: Maegawa, Shehorn, Kettelle, Jie.
Supervision: Maegawa, Aziz, Riall.
Conflict of Interest Disclosures: Dr Riall reports a portfolio of stock, none directly related to the work in this article, including Apple, AbbVie, Abbott Laboratories, Aegirum, Amgen, Boeing, Caterpillar, Colgate Palmolive, Canadian National Railway, Cisco Systems, Cintas Group, Chevron, Texaco, Dupont, Dow Chemical, General Dynamics, General Electric, General Mills, Alphabet Inc, Home Depot, Honeywell, IMB, Intel, Johnson and Johnson, Coca Cola, Lockheed Martin, McDonalds, Medtronic, McCormick, 3M, Microsoft, PepsiCo, Pfizer, Proctor and Gamble, Parker Hannifan, Sherwin Williams, St Jude Medical, Sysco, AT&T, United Health Group, Union Pacific, United Technologies, Verizon, Walgreens, Wells Fargo, Walmart, Xilinx, and Exxon. No other disclosures were reported.
Meeting Presentation: This study was presented at the Association of VA Surgeons Meeting; May 8, 2018; Miami Beach, Florida.
REFERENCES

1. National Comprehensive Cancer Network. Hepatobiliary (Version 5.2018). https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed November 18, 2018.

2. Adam R, Bhangui P, Vibert E, et al. Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg. 2012;256(6):883-891. doi:10.1097/SLA.Ob013e318273bad0

3. Koniaris LG, Levi DM, Pedroso FE, et al. Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg. 2011;254(3):527-537. doi:10.1097/SLA.Ob013e31822ca66f

4. Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2009;250(6):922-928. doi:10.1097/SLA.Ob013e3181b977a5

5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118-1127. doi:10.1056/NEJMra1001683

6. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485-1491. doi:10.1200/JCO.2008.20.7753

7. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699. doi:10.1056/NEJM199603143341104

8. Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer/H113492 cm: results from two Western centers. Hepatology. 2013;57(4):1426-1435. doi: 10.1002/hep.25832

9. Farges O, Malassagne B, Flejou JF, Balzani S, Sauvanet A, Belghiti J. Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg. 1999;229(2):210-215. doi: 10.1097/00000658-199902000-00008

10. Sterling RK, Lissen E, Clumeck N, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325. doi:10.1002/hep.21178

11. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-526. doi:10.1053/he.2003.50346

12. Hung HH, Su CW, Lai CR, et al. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int. 2010;4(4):691-699. doi:10.1007/s12072-010-9213-3

13. Shen SL, Fu SJ, Chen B, et al. Preoperative aspartateaminotransferase to platelet ratio is an independent prognostic factor for hepatitis B–induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol. 2014;21(2):3802-3809. doi:10.1245/s10434-014-3771-x

14. Ichikawa T, Uenishi T, Takemura S, et al. A simple, noninvasively determined index predicting hepatic failure following liver resection for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2009;16(1):42-48. doi:10.1007/s00534-008-0003-4

15. Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007;41(8):777-782. doi:10.1097/MCG.0b013e3180381560

16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. doi:10.1371/journal.pmed.0040296

17. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864-871. doi:10.1053/he.2000.5852

18. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649. doi:10.1002/bjs.1800600817

19. Sebastiani G, Tempesta D, Fattovich G, et al. Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: results of a multicenter, large-scale study. J Hepatol. 2010;53(4):630-638. doi:10.1016/j.jhep.2010.04.019

20. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486-1501. doi:10.1002/hep.29302

21. Kattan MW. Evaluating a new marker’s predictive contribution. Clin Cancer Res. 2004;10(3):822-824. doi:10.1186/1746-4328-03-0061

22. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543-2546. doi:10.1001/jama.1982.0332043047030
23. Dong J, Xu XH, Ke MY, et al. The FIB-4 score predicts postoperative short-term outcomes of hepatocellular carcinoma fulfilling the Milan criteria. Eur J Surg Oncol. 2016;42(5):722-727. doi: 10.1016/j.ejso.2016.02.009

24. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2

25. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A. A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. Surgery. 2015;157(4):699-707. doi: 10.1016/j.surg.2014.10.022

26. Davila JA, Kramer JR, Duan Z, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57(5):1858-1868. doi: 10.1002/hep.26287

27. Grazi GL, Ercolani G, Pierangeli F, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234(1):71-78. doi: 10.1097/00000658-200107000-00011

28. Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg. 2004;240(4):698-708.

29. Maithel SK, Kneuertz PJ, Kooby DA, et al. Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis. J Am Coll Surg. 2011;212(4):638-648. doi: 10.1016/j.jamcollsurg.2011.01.004

30. Venkat R, Hannallah JR, Krouse RS, Maegawa FB. Preoperative thrombocytopenia and outcomes of hepatectomy for hepatocellular carcinoma. J Surg Res. 2016;201(2):498-505. doi: 10.1016/j.jsr.2015.08.038

31. Wu CC, Ho WL, Yeh DC, Huang CR, Liu TJ, P'eng FK. Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? Surgery. 1996;120(1):34-39. doi: 10.1016/S0039-6060(96)80238-8